In his weekly clinical update, Dr. Griffin discusses the new risk assessment for the H5N1 avian flu viruses, the development of monoclonal antibody-based blocking ELISA for detecting SARS-CoV-2 exposure in animals, repeated antibiotic exposure and risk of hospitalization and death following COVID-19 infection, COVID-19 rebound study: a prospective cohort study to evaluate viral and symptom rebound differences in participants treated with Nirmatrelvir plus Ritonavir versus untreated controls, exaggerated blood pressure elevation in response to orthostatic challenge a post-acute sequelae of SARS-CoV-2 infection (PASC) after hospitalization, long term follow-up of a multicenter cohort of COVID-19 patients with pulmonary embolism, and risk of cardiovascular disease after COVID‐19 diagnosis among adults with and without diabetes.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• New risk assessment for H5N1 avian flu viruses (CDC)
• Development of monoclonal antibody-based blocking ELISA for detecting SARS-CoV-2 exposure (Virology)
• Repeated antibiotic exposure and risk of hospitalization and death following COVID-19 infection (eClinicalMedicine)
• COVID-19 Rebound Study (CID)
• Exaggerated blood pressure elevation in response to orthostatic challenge (AN)
• Long term follow-up of a multicenter cohort of COVID-19 patients with pulmonary embolism (TR)
• Risk of Cardiovascular disease after COVID‐19 diagnosis among adults with and without Diabetes (JAHA)
• Contribute to our FIMRC fundraiser at PWB
• Letters read on TWiV 1025
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]